Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03236857 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 143
- Enrollment target
NCT03236857 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 143 participants.
The verdict
NCT03236857, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 143 participants
- Enrollment target
Study Summary
An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.
Interventions
- DRUG venetoclax
- DRUG chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2017-11-08 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03236857
The ClinicalTrials.gov registry entry for NCT03236857 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which venetoclax is the first listed.
NCT03236857 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03236857 about?
NCT03236857 is a clinical study titled "A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies". An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with ...
What is the current status of trial NCT03236857?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 143 participants. The study started on 2017-11-08. Estimated completion is 2023-04-19.
What interventions are being tested in trial NCT03236857?
The interventions under investigation include: venetoclax (DRUG), chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03236857?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.